Foghorn Therapeutics Inc. develops precision therapeutics for serious diseases by targeting the chromatin regulatory system and correcting abnormal gene expression. The company’s news centers on oncology programs derived from its Gene Traffic Control® platform, including FHD-909, a selective SMARCA2 inhibitor for SMARCA4-mutant cancers, and selective CBP, EP300 and ARID1B degrader programs across ER+ breast cancer, multiple myeloma and other hematologic malignancies.
Recurring updates also cover the company’s collaboration with Lilly, preclinical data presentations, financial results, registered direct financing activity, executive appointments and investor-conference participation.
Foghorn Therapeutics announced the pricing of its initial public offering of 7,500,000 shares at $16.00 each, aiming to raise approximately $120 million. The underwriters have a 30-day option to purchase an additional 1,125,000 shares. Trading begins on October 23, 2020, under the ticker symbol 'FHTX'. The offering is set to close on October 27, 2020, subject to closing conditions. Goldman Sachs, Morgan Stanley, and Cowen are leading the offering, with a registration statement effective since October 22, 2020.